Search
Schrodinger Inc
SDGRAdd to Watchlist
16.880USD
+0.490+2.99%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.26BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.99%
5 Days
+0.12%
1 Month
+6.50%
6 Months
-6.12%
Year to Date
-5.59%
1 Year
-20.08%
Key Figures
16.630Open
17.625High
1.51MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.03%Turnover Ratio
16.390Prev. Close
16.545Low
19.25MTurnover
LossP/E Static
4.01P/B
0.00%Div Yield TTM
-15.03%ROA
27.63052wk High
1.05Volume Ratio
-187.12MNet Profit
74.55MShares
-1.3987EPS TTM
1.61Beta
-30.12%ROE
10.94552wk Low
6.59%Amplitude
50.43%Gross Margin
1.26BMarket Cap
1.09Reward/Risk
3.13%Risk Rate
TradingKey Stock Score of Schrodinger Inc
Currency: USD Updated: 2026-07-02Key Insights
Schrodinger Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 79 out of 486 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.57.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Schrodinger Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Schrodinger Inc Highlights
StrengthsRisks
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.09% year-on-year.
Undervalued
The company’s latest PE is -12.07, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 71.93M shares, decreasing 9.13% quarter-over-quarter.
Held by Bill Gates
Star Investor Bill Gates holds 13.85M shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
19.571
Target Price
+19.41%
Upside Space
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Schrodinger Inc Info
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Ticker SymbolSDGR
CompanySchrodinger Inc
CEOFarid (Ramy Farid)
Websitehttps://www.schrodinger.com
Related Instruments
-0.36%
-0.48%
+1.62%
-4.90%
+2.99%
+3.24%
-1.64%
+4.66%
+2.84%
+1.03%
-1.13%
-1.87%
+2.17%
-6.65%
-1.78%
+2.42%
+1.76%
-0.16%
-1.72%
+0.34%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Schrodinger Inc (SDGR)?
The current price of Schrodinger Inc (SDGR) is 16.88.
What is the symbol of Schrodinger Inc?
The ticker symbol of Schrodinger Inc is SDGR.
What is the 52-week high of Schrodinger Inc?
The 52-week high of Schrodinger Inc is 27.63.
What is the 52-week low of Schrodinger Inc?
The 52-week low of Schrodinger Inc is 10.95.
What is the market capitalization of Schrodinger Inc?
The market capitalization of Schrodinger Inc is 1.26B.
Is Schrodinger Inc (SDGR) currently rated as Buy, Hold, or Sell?
According to analysts, Schrodinger Inc (SDGR) has an overall rating of Buy, with a price target of 19.57.
What is the Earnings Per Share (EPS TTM) of Schrodinger Inc (SDGR)?
The Earnings Per Share (EPS TTM) of Schrodinger Inc (SDGR) is -1.41.